Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Bevacizumab + Chemotherapy in Advanced Biliary Tract Cancer
NCT07619235Phase 4Recruiting
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab + tuvonralimab in biliary tract cancer (BTC). Primary endpoint: Progression-Free Survival Rate at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07619235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619235.